Live feed10:16:00·30dPRReleasevia QuantisnowDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidatesByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
